CA2395493C - Hyaluronic acid in the treatment of cancer - Google Patents

Hyaluronic acid in the treatment of cancer Download PDF

Info

Publication number
CA2395493C
CA2395493C CA2395493A CA2395493A CA2395493C CA 2395493 C CA2395493 C CA 2395493C CA 2395493 A CA2395493 A CA 2395493A CA 2395493 A CA2395493 A CA 2395493A CA 2395493 C CA2395493 C CA 2395493C
Authority
CA
Canada
Prior art keywords
dna
grou
bacterial
cancer
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2395493A
Other languages
English (en)
French (fr)
Other versions
CA2395493A1 (en
Inventor
Mario C. Filion
Nigel C. Phillips
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Telesta Therapeutics IP Inc
Original Assignee
Bioniche Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc
Publication of CA2395493A1 publication Critical patent/CA2395493A1/en
Application granted granted Critical
Publication of CA2395493C publication Critical patent/CA2395493C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2395493A 1999-12-28 2000-12-28 Hyaluronic acid in the treatment of cancer Expired - Fee Related CA2395493C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17337599P 1999-12-28 1999-12-28
US60/173,375 1999-12-28
PCT/CA2000/001562 WO2001047561A1 (en) 1999-12-28 2000-12-28 Hyaluronic acid in the treatment of cancer

Publications (2)

Publication Number Publication Date
CA2395493A1 CA2395493A1 (en) 2001-07-05
CA2395493C true CA2395493C (en) 2010-06-22

Family

ID=22631719

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2395493A Expired - Fee Related CA2395493C (en) 1999-12-28 2000-12-28 Hyaluronic acid in the treatment of cancer

Country Status (8)

Country Link
US (1) US7125858B2 (cg-RX-API-DMAC7.html)
EP (1) EP1250152B1 (cg-RX-API-DMAC7.html)
JP (1) JP4215429B2 (cg-RX-API-DMAC7.html)
AU (1) AU784356B2 (cg-RX-API-DMAC7.html)
CA (1) CA2395493C (cg-RX-API-DMAC7.html)
DK (1) DK1250152T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ520312A (cg-RX-API-DMAC7.html)
WO (1) WO2001047561A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140198B1 (en) 1999-01-13 2007-10-31 Alchemia Oncology Pty Limited Use of hyaluronan for the manufacture of a medicament for the enhancement of the efficacy of cytotoxic drugs
US20020091095A1 (en) * 1999-12-13 2002-07-11 Phillips Nigel C. Modulation of Fas and FasL expression
DE60036019T2 (de) * 1999-12-13 2008-05-29 Bioniche Life Sciences Inc., Belleville Synthetische oligonukleotide die therapeutisch nützlich sind
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
WO2002061085A2 (en) 2000-10-31 2002-08-08 Ryan James W Isolated genomic polynucleotide fragments from the p15 region of chromosome 11
US7087586B2 (en) * 2001-04-24 2006-08-08 Bioniche Life Sciences, Inc. Oligonucleotide compositions and their use to induce differentiation of cells
ITPD20020271A1 (it) 2002-10-18 2004-04-19 Fidia Farmaceutici Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.
EP1625851A4 (en) 2003-05-16 2007-12-26 Bbk Bio Corp PREPARATION FOR PREVENTING CONTACT OF PATHOGEN BROOMS WITH A LIVING ORGANISM
US20060240084A1 (en) * 2005-04-20 2006-10-26 Xylos Corporation Microbial cellulose materials for use in transdermal drug delivery systems, method of manufacture and use
CA2616607C (en) * 2005-07-27 2015-06-02 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
EP1922077A4 (en) * 2005-09-07 2013-03-06 Alchemia Oncology Pty Ltd THERAPEUTIC COMPOSITIONS WITH HYALURON AND THERAPEUTIC ANTIBODIES AND TREATMENT PROCEDURES
CN101848702B (zh) 2006-12-01 2013-07-17 安特里奥公司 两亲实体纳米粒子
DE102009035586A1 (de) 2009-07-31 2011-02-03 Fresenius Kabi Deutschland Gmbh Intravesikale Instillationslösungen zur Behandlung von Blasenkrebs
NO2480669T3 (cg-RX-API-DMAC7.html) * 2009-09-25 2018-04-07
WO2012049654A1 (en) 2010-10-13 2012-04-19 Bioniche Life Sciences, Inc. Bacterial ribonucleic acid cell wall compositions and methods of making and using them
JP2016537685A (ja) * 2013-09-12 2016-12-01 ディーエスエム アイピー アセッツ ビー．ブイ． 眼球デバイス
EP3541358A1 (en) 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Transdermal delivery of large agents
WO2020056191A1 (en) 2018-09-13 2020-03-19 Eirion Therapeutics, Inc. Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors
US12702790B2 (en) 2019-06-13 2026-08-11 Hollister Incorporated Reusable urinary catheter kits
LT3952973T (lt) 2019-06-13 2023-07-10 Hollister Incorporated Daugkartinio naudojimo šlapimo kateterio produktai
WO2020263859A1 (en) 2019-06-25 2020-12-30 Hollister Incorporated Reusable urinary catheter products
US20210000910A1 (en) 2019-07-03 2021-01-07 Jysk Skin Solutions Pte Ltd Topical compositions
JP7500038B2 (ja) * 2019-08-27 2024-06-17 国立研究開発法人物質・材料研究機構 炎症性サイトカイン産生抑制材、ヒアルロン酸誘導体、及び、ヒアルロン酸誘導体の製造方法。
CA3181682A1 (en) * 2020-07-17 2022-01-20 Anil Kapur Subcutaneous telomerase inhibitor compositions and methods for using same
US12083204B2 (en) 2022-06-02 2024-09-10 L'oreal Topical composition for homeostatic delivery of nitric oxide and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172815A (en) * 1962-04-24 1965-03-09 Warner Lambert Pharmaceutical Method for preparing reticulo-endo-thelial system stimulant and stimulant thereof
US4152423A (en) * 1971-11-19 1979-05-01 Agence Nationale De Valorisation De La Recherche (Anvar) Immunological agents
FR2160326B1 (cg-RX-API-DMAC7.html) * 1971-11-19 1975-02-07 Anvar
CA1020460A (en) * 1973-02-23 1977-11-08 Wellcome Foundation Limited (The) Isolation of immunostimulating glycopeptide from bacteria
US3976544A (en) * 1973-06-19 1976-08-24 The Agence Nationale De Valorisation De Le Recherche Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction
FR2374042A1 (fr) * 1976-06-04 1978-07-13 Merieux Inst Nouveau medicament immunostimulant et son procede de preparation
JPS54140710A (en) * 1978-03-10 1979-11-01 Mitsui Toatsu Chem Inc Anti-tumor substance and its preparation
DE3011461C2 (de) * 1980-03-25 1986-10-30 Dr. Madaus & Co, 5000 Köln Verwendung von Propionibakterien
US4520019A (en) * 1982-04-29 1985-05-28 Ribi Immunochem Research, Inc. Stable composition and preparation thereof
US4579941A (en) * 1982-08-13 1986-04-01 Mitsuitoatsu Chemicals, Inc. Thermally-denatured deoxyribonucleic acid MD-011 and antitumor agent
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
DE3408768A1 (de) 1984-03-09 1985-09-12 Bayer Ag, 5090 Leverkusen Immunstimulierende mittel
US4744984A (en) * 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
DE3689071T2 (de) 1985-10-31 1994-02-10 Univ Australian Immunheilbehandlung.
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4837202A (en) 1987-09-14 1989-06-06 Pitman-Moore, Inc. Method for stimulating the immune system
DE3818054C2 (de) 1988-05-27 1994-02-17 Biotest Pharma Gmbh Verwendung einer Kombination aus einem Antigen bzw. einer Vakzine und humanem Interleukin zur Behandlung der Non-Responsiveness gegenüber immunologischen Defektzuständen
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
EP0952855B1 (en) * 1991-07-03 2005-07-27 Meditech Research Limited Use of hyaluronan in gene therapy
CA2122519C (en) 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
AU691797B2 (en) * 1993-01-29 1998-05-28 Vetrepharm, Inc. Immunotherapeutic composition
AU6362594A (en) 1993-03-10 1994-09-26 Miles Inc. Hyaluronic acid used as a cancer treatment
IN181358B (cg-RX-API-DMAC7.html) * 1995-02-14 1998-05-30 Bioniche Inc
AU1991097A (en) 1996-03-15 1997-10-01 Immunotherapy, Inc. Dialdehydes as immunostimulatory adjuvants and cross-linkers for producing immunogenic preparations and generating pressure and cross-linked treated cells for enhancing and augmenting the immune response against cancers, tumors and pathogenic diseases
CA2208924A1 (en) 1997-07-09 1999-01-09 Hyal Pharmaceutical Corporation Sparing paclitaxel by the use of hyaluronan
KR100533576B1 (ko) * 1997-08-05 2005-12-05 바이오니취 라이프 사이언시즈 인코포레이티드 세포증식 및 세포사멸 조절용 조성물 및 방법
NZ506406A (en) 1998-02-18 2002-11-26 Bioniche Life Sciences Inc Compositions comprising Mycobacterium phlei DNA and methods for its use in the treatment of bladder cancer
WO2000033875A1 (en) 1998-12-04 2000-06-15 Bioniche Life Sciences Inc. Chemotherapeutic composition and method
EP1140198B1 (en) * 1999-01-13 2007-10-31 Alchemia Oncology Pty Limited Use of hyaluronan for the manufacture of a medicament for the enhancement of the efficacy of cytotoxic drugs
CA2266188A1 (en) 1999-03-19 2000-09-19 Stephen Chizick Natural preparation for treatment of male pattern hair loss

Also Published As

Publication number Publication date
EP1250152A1 (en) 2002-10-23
AU784356B2 (en) 2006-03-16
JP2003518510A (ja) 2003-06-10
US7125858B2 (en) 2006-10-24
AU2336401A (en) 2001-07-09
JP4215429B2 (ja) 2009-01-28
DK1250152T3 (da) 2013-08-26
WO2001047561A1 (en) 2001-07-05
NZ520312A (en) 2003-08-29
US20030176381A1 (en) 2003-09-18
EP1250152B1 (en) 2013-05-15
CA2395493A1 (en) 2001-07-05

Similar Documents

Publication Publication Date Title
EP1250152B1 (en) Synergistic composition containing hyaluronic acid in the treatment of cancer
Zhang et al. Anti-tumor macrophages activated by ferumoxytol combined or surface-functionalized with the TLR3 agonist poly (I: C) promote melanoma regression
ES2409755T3 (es) Método para Tratar el Cáncer Utilizando un Agente Anticanceroso Combinado
Watkins-Schulz et al. A microparticle platform for STING-targeted immunotherapy enhances natural killer cell-and CD8+ T cell-mediated anti-tumor immunity
Tang et al. A blood–brain barrier-and blood–brain tumor barrier-penetrating siRNA delivery system targeting gliomas for brain tumor immunotherapy
Huang et al. Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunotherapy
Wittig et al. MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside
ES2288883T3 (es) Oligonucleotidos sinteticos utiles terapeuticamente.
CN109069528B (zh) DBait分子在制备用于治疗三阴性乳腺癌的药物中的用途
MXPA04004998A (es) Metodos para tratar cancer mediante la utilizacion de una combinacion de un antagonista del factor inhibidor de celula dentritica derivado de tumor y un antagonista del receptor de tipo toll.
Jordan et al. CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model
Groer et al. Intratumoral cancer chemotherapy with a carrier-based immunogenic cell death eliciting platinum (IV) agent
WO2025016479A1 (zh) 核酸载体、核酸药及其制备方法和应用
JP5667043B2 (ja) 阻害性オリゴヌクレオチドを送達するための組成物および方法
JP6536964B2 (ja) 免疫賦活活性を有する核酸多糖複合体の抗腫瘍薬としての応用
US7662792B2 (en) Modulation of Fas and FasL expression
Zhao et al. Polymersome-enabled brain codelivery of STAT3 siRNA and CpG oligonucleotide boosts chemo-immunotherapy of malignant glioma
Mizuno et al. Simultaneous delivery of doxorubicin and immunostimulatory CpG motif to tumors using a plasmid DNA/doxorubicin complex in mice
Zhu et al. Intestinal probiotic-based nanoparticles for cytotoxic siRNA delivery in immunotherapy against cancer
JP7048102B2 (ja) 免疫賦活活性を有する核酸多糖複合体の抗腫瘍薬としての応用
CN102703447B (zh) 一种具有治疗乳腺癌作用的寡核苷酸
Simpson et al. Hyaluronan signaling and turnover
CN101333237B (zh) 一种具有治疗乳腺癌作用的寡核苷酸
KR20040047749A (ko) 올리고뉴클레오타이드 조성물 및 세포 분화 유도시 이의용도
CN101688205B (zh) 抗肿瘤药物、药剂、组合物及其用途

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20151229